Adagio Therapeutics Stock News

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of d

Last Friday, health care focused hedge fund M28 Capital filed a 13D/A with the US Securities & Exchange Committee revealing it bought 2.85 million Adagio Therapeutics (US:ADGI) at an average of $4.28

The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, G

Adagio Therapeutics Inc's (NASDAQ: ADGI) Phase 2/3 trials evaluating 300 mg adintrevimab (ADG20) as pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19 have met its primary

Investors are reacting to better than expected clinical trial results for its COVID-19 treatment candidate.

Adagio Therapeutics Inc (NASDAQ: ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the first monoclonal antibody to meet primary endpoin

Adagio Therapeutics says it will seek an emergency use authorization for its Covid-19 antibody, known as ADG20, in the second quarter.

Here's what you need to know about trading penny stocks on March 30th The post Trading Penny Stocks? Top Stock Market News for March 30th, 2022 appeared first on Penny Stocks to Buy, Picks, News and I

There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe there is a lot to gain in these stocks after the market reprices shares to near

Adagio Therapeutics (ADGI) appointed David Hering as interim CEO, effective immediately.Hering, who will also remain ADGI''s COO, succeeds Tillman Gerngross, who resigned as CEO…

Adagio Therapeutics Inc (NASDAQ: ADGI ) has outlined strategic initiatives for its ADG20 program and research efforts to address SARS-CoV-2 and other coronaviruses. ADG20 is an investigational monoclonal antibody (mAb) being developed to prevent and treat COVID-19. Adagio plans to analyze clinical data from its global Phase 2/3 clinical trials for the prevention (EVADE study) and treatment (STAMP study) of COVID-19 to assess the preliminary safety Full story available on Benzinga.com

The clinical-stage biopharmaceutical company Adagio Therapeutics (ADGI) has lost ~6% in the premarket on Tuesday after the company announced the resignation of its Chief Executive

Three recent independent in-vitro studies show that ADG20 has neutralization activity against Omicron.

In the last trading session, 2.39 million shares of the Adagio Therapeutics Inc. (NASDAQ:ADGI) were traded. Most recently the company’s share price was $6.39, and it changed around -$0.61 or -8.71% from the last close, which brings the market valuation of the company to $745.46M. ADGI currently trades at a discount to its 52-week high … Adagio Therapeutics Inc. (NASDAQ: ADGI) Could See Prices Soar In The Coming Months Read More »